799 related articles for article (PubMed ID: 22275291)
1. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Stohl W; Hiepe F; Latinis KM; Thomas M; Scheinberg MA; Clarke A; Aranow C; Wellborne FR; Abud-Mendoza C; Hough DR; Pineda L; Migone TS; Zhong ZJ; Freimuth WW; Chatham WW; ;
Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
[TBL] [Abstract][Full Text] [Related]
2. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
3. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
[TBL] [Abstract][Full Text] [Related]
5. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
6. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
[TBL] [Abstract][Full Text] [Related]
7. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
[TBL] [Abstract][Full Text] [Related]
8. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
9. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
11. Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A
Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Front Immunol; 2022; 13():796508. PubMed ID: 35444642
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
Jacobi AM; Huang W; Wang T; Freimuth W; Sanz I; Furie R; Mackay M; Aranow C; Diamond B; Davidson A
Arthritis Rheum; 2010 Jan; 62(1):201-10. PubMed ID: 20039404
[TBL] [Abstract][Full Text] [Related]
13. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
Chatham WW; Wallace DJ; Stohl W; Latinis KM; Manzi S; McCune WJ; Tegzová D; McKay JD; Avila-Armengol HE; Utset TO; Zhong ZJ; Hough DR; Freimuth WW; Migone TS;
J Rheumatol; 2012 Aug; 39(8):1632-40. PubMed ID: 22707609
[TBL] [Abstract][Full Text] [Related]
14. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
15. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.
Sohrabian A; Parodis I; Carlströmer-Berthén N; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I; Rönnelid J
Arthritis Res Ther; 2019 Nov; 21(1):259. PubMed ID: 31783909
[TBL] [Abstract][Full Text] [Related]
17. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA;
Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
[TBL] [Abstract][Full Text] [Related]
18. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
Lokhandwala T; Yue B; Coutinho AD; Bell CF
Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436
[TBL] [Abstract][Full Text] [Related]
19. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE.
van Dam LS; Osmani Z; Kamerling SWA; Kraaij T; Bakker JA; Scherer HU; Rabelink TJ; Voll RE; Alexander T; Isenberg DA; van Kooten C; Teng YKO
Rheumatology (Oxford); 2020 Oct; 59(10):2734-2745. PubMed ID: 31951278
[TBL] [Abstract][Full Text] [Related]
20. Belimumab: in systemic lupus erythematosus.
Burness CB; McCormack PL
Drugs; 2011 Dec; 71(18):2435-44. PubMed ID: 22141386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
